期刊
ONCOIMMUNOLOGY
卷 10, 期 1, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2021.1942673
关键词
Hepatocellular carcinoma; Natural killer cells; TIGIT; TIM-3; co-expression
资金
- Special Fund of Capital Health Research and Development [2020-2-2173]
- National Science Foundation of China [81874435, 81902895]
- Dengfeng Talent Support Program of Beijing Municipal Administration of Hospitals [DFL20191803]
- Fund for Beijing Science & Technology Development of Traditional Chinese Medicine [JJ-2020-52]
- Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support [ZYLX202127]
- National Natural Science Foundation of China
Research has found that the co-expression of TIGIT and TIM-3 on NK cells is elevated in patients with HBV-HCC, leading to functional dysfunction that may be closely related to disease progression.
The prognosis of hepatocellular carcinoma (HCC) is extremely poor, of which hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) accounts for the majority in China. Immune checkpoint inhibitors have become an effective immunotherapy method for the treatment of HCC, but they are mainly used for T cells. NK cells play a vital role as the first line of defense against tumors. Therefore, we explored the characteristic expression pattern of immune checkpoints on NK cells of HBV-HCC patients. We analyzed the correlation between the co-expression of TIGIT and TIM-3 and the clinical progress of patients with HBV-HCC. The co-expression of TIGIT and TIM-3 on NK cells is elevated in patients with HBV-HCC. TIGIT(+)TIM-3(+)NK cells showed exhausted phenotypic characteristics and displayed dysfunction manifested as weakened killing function, reduced cytokine production, and proliferation function. TIGIT(+)TIM-3(+)NK cells participate in NK cells function exhaustion and are closely related to the disease progression of patients with HBV-HCC, suggesting a new target for future immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据